Skip to main content
Premium Trial:

Request an Annual Quote

Friel to Take the Helm at PerkinElmer, Bender Named CEO of Interleukin Genetics, Clinical Data Appoints New Execs, and More

NEW YORK (GenomeWeb News) - PerkinElmer this week said that company President and Chief Operating Officer Robert Friel will take over the chief executive efficer post from Gregory Summe on Feb. 1. In accordance with the company’s planned strategy for succession of responsibility, Summe will continue to hold his post as executive chairman of the board through April 2009.
 
Friel, who started at PerkinElmer in 1999 as chief financial officer and was promoted to president and COO in 2007, will retain his post as president.
 

 
Epigenomics has named Richard Wender to the company’s medical advisory board for colorectal cancer screening.
 

 
Interleukin Genetics has appointed Lewis Bender to the post of CEO. Bender has been involved in biotechnology for over 15 years as a senior executive, including holding the post of senior VP of business development and VP of manufacturing and CTO at Emisphere Technologies.
 

 
The National Human Genome Research Institute brought in Kathy Kopnisky as chief of staff in the Immediate Office of the Director. Acting Chief Laura Lyman Rodriguez will return to take on policy matters as senior advisor to the director for research policy.
 
Kopnisky arrives at NHGRI from the National Institute of Mental Health, where she most recently was chief of HIV Therapeutics/Clinical Trials and Psychiatric Programs. Rodriguez has been with NHGRI since 2002 as a health policy analyst and as special advisor to the director.
 

 
Transgenomic has appointed Eric Kaldjian to the job of chief scientific officer. Kaldjian formerly was executive director of medical sciences at Gene Logic, and he was an oncology and experimental medicine researcher at Pfizer Global Research and Development. In his new office, Kaldjian will lead Transgenomic’s R&D and biomarker research.
 

 
Clinical Data has named Meeta Patnaik to be senior VP of predictive diagnostics and Marcia Lewis to the post of VP of biomarker development.
 
Patnaik formerly was chief medical officer at Lipomics Technologies and was a founder of Pathway Diagnostics, where she also was senior VP and chief science and technology officer. Lewis recently was senior director of oncology at Celera and was director of genomics and bioinformatics, among other titles, at Bayer Diagnostics.
 

 
ITI Life Sciences has appointed Ford Kennedy to the job of director of commercialization. Kennedy previously was director of scientific sourcing and new technologies at Millipore.
 

 
Michael Salgaller has been named COO of Calibrant Biosystems. Salgaller has been an advisor to Calibrant, a member of an investment team at Toucan Capital, VP of clinical research affairs at Northwest Biotherapeutics, and a senior staff scientist at the National Institutes of Health.
 
Calibrant also has promoted Brian Balgley to the position of chief technology officer. Balgley has been serving as the company’s director of proteomics in its drug discovery program.
 

 
BioForce Nanosciences has shuffled its management, making President and COO Kerry Frey the new CEO, while retaining the title of president, and moving current CEO Eric Henderson into the post of executive VP and CSO, a newly created position.
 

 
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.